Publikationen in Zusammenarbeit mit Forschern von Hospital Carlos III (110)

2020

  1. Coronavirus and other airborne agents with pandemic potential

    Current Opinion in Environmental Science and Health, Vol. 17, pp. 41-48

  2. Long-acting antiretroviral therapy

    Nature Materials, Vol. 19, Núm. 8, pp. 826-827

2015

  1. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 20, Núm. 3, pp. 329-334

  2. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 20, Núm. 1, pp. 65-72

  3. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  4. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy

    Journal of Viral Hepatitis, Vol. 21, Núm. 7, pp. 475-479

  2. Dolutegravir, abacavir and lamivudine as HIV therapy

    Expert Opinion on Pharmacotherapy, Vol. 15, Núm. 7, pp. 1051-1057

  3. Efficacy of prolonged tenofovir therapy on Hepatitis delta in HIV-infected patients

    AIDS, Vol. 28, Núm. 16, pp. 2389-2394

  4. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  5. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

  6. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients

    Clinical Infectious Diseases, Vol. 58, Núm. 11, pp. 1549-1553

  7. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy

    Antiviral Therapy, Vol. 19, Núm. 3, pp. 287-292

  8. Management and treatment of chronic hepatitis B in HIV-positive patients

    Annals of Medicine, Vol. 46, Núm. 5, pp. 290-296

  9. Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain

    AIDS Research and Human Retroviruses, Vol. 30, Núm. 9, pp. 856-862

  10. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  11. Pharmacogenetics of antiretroviral therapy

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Núm. 8, pp. 1119-1130

  12. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies

    Antiviral Therapy, Vol. 19, Núm. 8, pp. 799-803

  13. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy

    AIDS, Vol. 28, Núm. 10, pp. 1473-1478

  14. Towards hepatitis C eradication from the HIV-infected population

    Antiviral Research